

## Data Sharing Statement

Zirwas. Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis. *JAMA Dermatol*. Published May 03, 2023. doi:10.1001/jamadermatol.2023.0846

### Data

**Data available:** Yes

**Data types:** Other (please specify)

**Additional Information:** Data collected for these studies will be made available to others. Proposals for data requests will be reviewed and considered for sharing following approval of the indication. Information about when data availability will begin and end will be provided following approval of the indication.

**How to access data:** Data collected for these studies will be made available to others. Proposals for data requests will be reviewed and considered for sharing following approval of the indication. Information about when data availability will begin and end will be provided following approval of the indication.

**When available:** With publication

### Supporting Documents

**Document types:** None

### Additional Information

**Who can access the data:** Anyone requesting the data

**Types of analyses:** Data collected for these studies will be made available to others. Proposals for data requests will be reviewed and considered for sharing following approval of the indication. Information about when data availability will begin and end will be provided following approval of the indication.

**Mechanisms of data availability:** Data collected for these studies will be made available to others. Proposals for data requests will be reviewed and considered for sharing following approval of the indication. Information about when data availability will begin and end will be provided following approval of the indication.